NCT00890162: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT00890162 |
|---|---|
| Title | A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 27, 2009 |
| Completion date | July 31, 2018 |
| Required reporting date | July 31, 2019, midnight |
| Actual reporting date | June 12, 2019 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |